Build a Multi-Camera Autonomous AI Eye-Screening Platform

1. 1

   Define the multi-disease, multi-camera scope

   The differentiated product detects several sight-threatening conditions (diabetic retinopathy, age-related macular degeneration, and glaucomatous optic nerve damage) in one screening test, and is cleared to operate across multiple camera manufacturers rather than a single pairing. Multi-camera clearance is a major strategic advantage because it frees deployments from one hardware vendor. Each additional disease and each additional camera is a separate validation and regulatory scope. Define exactly what the platform is cleared to detect, and say so plainly, because autonomy only holds inside that scope.

2. 2

   Build the datasets and models per disease

   Each disease needs its own large, diverse, expertly labeled dataset, and the models must perform across the range of cameras you intend to clear. One documented multi-disease system reports 94.4 percent sensitivity and 91.1 percent specificity for more-than-mild disease and has screened more than 230,000 patients globally, which shows the achievable bar but is that system's context, not a promise. Data breadth across devices and populations is what makes multi-camera clearance possible. Invest in the data first.

3. 3

   Run the clinical validation and secure FDA clearance

   Each cleared use requires prospective clinical evidence and FDA authorization, and multi-camera support multiplies the validation work because each hardware pairing is validated separately. Regulatory strategy has to sequence which diseases and cameras to clear first for the fastest path to a usable product. This is a multi-year, capital-heavy effort. Build the regulatory roadmap before the engineering roadmap.

4. 4

   Anchor the business on CPT 92229 reimbursement

   The single biggest commercial unlock is that autonomous AI retinal screening is reimbursable under CPT code 92229, which turns the screening from a cost into billable revenue for the buyer. Diabetic retinopathy screening with AI is also a HEDIS quality measure for most health plans, which pushes payers and providers toward adoption. Building the product and pricing so the reimbursement flows cleanly is as important as the algorithm. The billing code is the market, not a detail.

5. 5

   Deploy per-scan across primary care and safety-net sites

   The buyers are primary care physicians, federally qualified health centers, telehealth organizations, and diabetes clinics, where minimally trained staff capture images and the AI returns a result on the spot within its cleared scope. Revenue is per-scan, and the value proposition is catching sight-threatening disease early where patients already are, without an on-site specialist. Multi-disease detection in one visit raises the clinical value per screen. Sell the reimbursed workflow, not the model in the abstract.

6. 6

   Scale the deployment and defend the moat

   Growth is adding sites, adding cameras, adding diseases, and expanding into new geographies and payer relationships, each of which compounds on the same core models. The moats are the clinical evidence base, the breadth of cleared cameras, the reimbursement relationships, and the installed screening volume. Ongoing post-market monitoring and quality reporting keep the clearance and payer trust intact. Treat regulatory and reimbursement breadth as the durable competitive advantage.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.

Best for: Medical AI founders and teams building a multi-disease, multi-camera screening platform

Not for: Not for anyone expecting a fast software launch; this is a multi-year, capital-heavy clinical and regulatory build. Not for a team unwilling to invest in representative data and rigorous validation, because a biased or unvalidated model fails in the field and in front of the FDA. And not for anyone who wants to market autonomy loosely, because autonomy is legitimate only inside the precise cleared scope and overstating it is both illegal and dangerous.